在勒维体阴性LRRK2-突变病例中,大量的非包含α-synuclein病理
Nanna Møller Jensen1,2, Zagorka Vitic3,4, Mia R Antorini3,4
1DANDRITE - Danish Research Institute of Translational Neuroscience, Aarhus C, Denmark. nanna.mj@biomed.au.dk.
Acta neuropathologica
|May 2, 2025
概括
像帕金森病这样的Lewy体疾病,涉及α-synuclein聚合. 这项研究表明,即使没有可见的勒维体,LRRK2相关的帕金森病也显示出显著的α-synuclein积累,这表明包含形成中的缺陷.
科学领域:
- 神经退行性疾病的神经退行性疾病
- 神经病理学神经病理学
- 帕金森病的遗传学
背景情况:
- 列维体疾病,包括帕金森病 (PD) 和列维体痴呆症,以α-synuclein包容 (列维体) 为特征.
- 一些单一的PD病例,特别是那些涉及LRRK2突变的病例,临床上呈现出勒维体病,但在神经病理上缺乏勒维体.
- 与LRRK2相关的PD中的神经病理表现可以显著变化,甚至在家庭内.
研究的目的:
- 为了研究莱维体阴性LRRK2相关的帕金森病中的α-synuclein聚合.
- 为了比较LRRK2病例中的α-synuclein积累模式与神经病理验证的勒维体疾病和健康对照.
- 为了确定勒维体阴性LRRK2-PD是否涉及缺少α-synuclein聚合或包含形成缺陷.
主要方法:
- 使用与MJFR14-6-4-2抗体的近距离结合试验 (PLA) 来检测α-synuclein.
- 分析了来自六名勒维体阴性LRRK2病例,五名勒维体疾病患者和六名健康对照者的脑组织.
- 量化和特征的α-synuclein聚合模式,区分包括和不包括的形式.
主要成果:
- 在勒维体阴性LRRK2病例中检测到广泛的α-synuclein积累,主要是作为颗粒PLA信号 (非包含聚合物).
- 晚期的勒维体病病例显示了勒维类和颗粒性PLA信号.
- 在LRRK2病例的脑干 (pontocerebellar通道和下橄叶核) 中观察到突出颗粒性PLA信号,与异常性Lewy体疾病不同.
结论:
- 与莱维体阴性LRRK2相关的帕金森病与显著的α-synuclein聚合有关.
- 在这些病例中,神经病理似乎涉及到Lewy体内涵的形成缺陷,而不是缺乏聚合.
- 这些发现凸显了LRRK2相关的PD中α-synuclein病理学的独特机制.
相关概念视频
Neural Regulation
39.0K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.0K
Lysosomal Hydrolases
3.7K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.7K
Parkinson's Disease: Overview
308
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
308
Amyloid Fibrils
9.0K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.0K


